Navigation Links
Astellas Responds to OSI Pharmaceuticals' Rejection
Date:3/15/2010

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 14,200 employees worldwide.  The organization is committed to becoming a global category leader in urology, immunology & infectious diseases, neuroscience, DM complications & metabolic diseases and oncology. For more information on Astellas Pharma Inc., please visit our website at http://www.astellas.com/en.

Important Additional Information

This communication is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell OSI Pharmaceuticals ("OSI") common stock. The tender offer (the "Tender Offer") is being made pursuant to a tender offer statement on Schedule TO (including the Offer to Purchase, Letter of Transmittal and other related tender offer materials) filed by Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc. (collectively, "Astellas") with the Securities and Exchange Commission ("SEC"). These materials, as they may be amended from time to time, contain
'/>"/>

SOURCE Astellas Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. FDA Approves Additional Indication for Astellas MYCAMINE(R)
3. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
4. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
5. Astellas Announces New Vice President of Marketing
6. Astellas Hires New Vice President of Compliance
7. Astellas Adds CNS Therapy Area Leader to Global R&D Team
8. Astellas Names Head of Global R&D Operations
9. NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
10. AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners
11. Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... WA (PRWEB) , ... July 31, 2015 , ... BioViva ... transforming the way we treat aging diseases. , BioViva announces it has begun ... treat patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® ... women experienced spontaneous migration of their Implanon® implants, inability to locate the implants, ...
(Date:7/31/2015)... Calgary, AB (PRWEB) , ... July 31, 2015 , ... ... changes. "When patients don't experience angina until a heart rate of 150 beats versus ... Fit Clinic in Calgary. "We are able to give life back to patients with ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... RenovoCath,™ a novel catheter that was developed for targeted delivery of fluids to ... now being treated at Florida Hospital Tampa with the device that provides direct, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels ... a study published today in Nature Communications and led by researchers from the Icahn ... that variations in the gene RTN1 led to greater production of the related RNT1 ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3
... Hometown Huddle Day and Air ... ... &,Human Services (HHS), the Ad Council and the National Football League (NFL),will ... to combat childhood obesity by encouraging physical,activity among children. The new ads, ...
... 9 Friends of Morongo fire chief,Phil Kelleher are ... raise,funds for him and his family. Widely known and ... lateral sclerosis (ALS),also known as Lou Gehrig,s disease. ... cells in the brain and spinal cord resulting in ...
... $260,000 for ORBIS Children,s Eye Care Project ... ... Lehka Pendyala, ages 8 and 6,will launch a kid-inspired and kid-driven campaign ... Their,ultimate goal is to raise $260,000 for a specialized pediatric eye care,unit ...
... COLUMBUS, Ohio -- Nurses and physicians at Nationwide Childrens Hospital ... endure the extreme pain of dressing changes and wound care. ... music, Nationwide Childrens Hospital Burn Center is now using virtual ... patients burn wounds. , Its long been known ...
... unveiled at Healthcare Communications Forum, November 5, ... ... today announced,seven finalists for the 2007 Insight Award for Customer Advocacy in,Healthcare. ... of health care services need,to make fully informed choices and successful purchase ...
... Pharmaceuticals,Inc. (Nasdaq: NPSP ) announced today that ... AstraZeneca to discover and develop drugs targeting,metabotropic glutamate ... million to acquire NPS,s assets related to the ... NPS intends to use the,proceeds to support further ...
Cached Medicine News:Health News:Video and Photo: U.S. Department of Health & Human Services and Ad Council Join NFL to Combat Childhood Obesity 2Health News:Video and Photo: U.S. Department of Health & Human Services and Ad Council Join NFL to Combat Childhood Obesity 3Health News:Video and Photo: U.S. Department of Health & Human Services and Ad Council Join NFL to Combat Childhood Obesity 4Health News:Fundraiser Announced for Morongo Fire Chief; Veteran Firefighter Diagnosed With ALS 2Health News:Fundraiser Announced for Morongo Fire Chief; Veteran Firefighter Diagnosed With ALS 3Health News:Elementary School Students to Launch 'Kids for Sight' Campaign, to Inspire Other Kids to Pay it Forward 2Health News:Elementary School Students to Launch 'Kids for Sight' Campaign, to Inspire Other Kids to Pay it Forward 3Health News:Virtual game helps children escape realities of burn unit 2Health News:NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development 2
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today announced that Robert A. Ingram has ... is an ardent champion for innovation in the lifesciences industry, ... on Edwards, board as we pursue our focused innovation strategy," ... "Bob has provided a valuable perspective to our board, drawing ...
(Date:7/30/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $453.1 million, a 9 percent ... (a 17 percent increase on a constant currency basis). ... ended June 30, 2014.  Diluted earnings per share for ... June 30, 2014.  The results for ...
(Date:7/30/2015)... July 30, 2015  Unichem Pharmaceuticals ( USA ... of Hydrochlorothiazide tablets 25 mg 1000-count bottle to the ... precautionary measure due to the identification of a Clopidogrel ... The risk associated with mistakenly taking a ... increased probability of experiencing Clopidogrel,s side effects which include ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... ... at ADA 2008, ... today announced data showing that the use of mealtime,SYMLIN(R) (pramlintide acetate) ... achieving diabetes treatment goals of,improved glucose control without weight gain or ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... with AZ-002 (Staccato(R),alprazolam) in patients with panic disorder. ... which were the effect of AZ-002 on the ... of AZ-002 on the duration of a,doxapram-induced panic ...
Cached Medicine Technology:Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 2Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 4Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 5Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: